Status:
COMPLETED
Study Evaluating The Tolerability Of Multiple Doses Of HKI-272
Lead Sponsor:
Puma Biotechnology, Inc.
Conditions:
Healthy Subjects
Eligibility:
All Genders
18-50 years
Phase:
PHASE1
Brief Summary
Study to investigate the occurence of diarrhea after either once daily or twice daily dosing for 14 days.
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Healthy male and female (non-child bearing potential) subjects
- Ages 18-50.
Exclusion
Key Trial Info
Start Date :
October 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2008
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00757809
Start Date
October 1 2008
End Date
October 1 2008
Last Update
May 14 2012
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Austin, Texas, United States, 78752
2
Tacoma, Washington, United States, 98418